PT-141 (Bremelanotide)

PT-141 (Bremelanotide), sold as Vyleesi, is the first FDA-approved medication that works through the brain to increase sexual desire. Unlike Viagra-type drugs that improve blood flow, PT-141 activates desire at its source — your central nervous system. **How does it work?** PT-141 activates melanocortin-4 receptors (MC4R) in your hypothalamus, the brain region that controls sexual arousal. It essentially "turns on" the neural pathways responsible for wanting sex, not just the physical ability to have it. **What the research shows:** • FDA-approved for hypoactive sexual desire disorder (HSDD) in premenopausal women • Clinical trials showed significant increases in desire, arousal, and satisfaction • Works within 45 minutes of injection • Effects can last up to 24 hours • Also studied for male erectile dysfunction (though not approved for this) **The discovery story:** PT-141 came from Melanotan II research. Scientists developing a tanning peptide noticed unexpected sexual arousal effects — leading to a whole new drug. **Common side effects:** Nausea (about 40% of users), flushing, and headache. Most side effects are temporary. **Important to know:** Administered as a subcutaneous injection at least 45 minutes before anticipated activity. Limited to 8 doses per month. --- **Sources:** FDA Prescribing Information for Vyleesi (2019) | Kingsberg SA, et al. (2019) Obstetrics & Gynecology | Clayton AH, et al. (2016) Journal of Sexual Medicine

Approval is limited to premenopausal women with acquired, generalized HSDD; benefits are modest, nausea is frequent, blood pressure elevations warrant warnings in hypertensive or cardiovascular patients, and long-term data are still accumulating. Use in men or as a general 'libido' drug is not approved.

Bremelanotide is a cyclic heptapeptide melanocortin receptor agonist (MC1R/MC3R/MC4R) administered by subcutaneous injection (Vyleesi 1.75 mg) on demand, with effects on desire typically beginning within about an hour. As a peptide it has limited oral bioavailability.